Targeting interferon-alpha to dendritic cells enhances a CD8(+) T cell response to a human CD40-targeted cancer vaccine.

Related Articles

Targeting interferon-alpha to dendritic cells enhances a CD8(+) T cell response to a human CD40-targeted cancer vaccine.

Vaccine. 2017 Jul 22;:

Authors: Graham JP, Authie P, Karolina Palucka A, Zurawski G

Abstract
Targeting antigens to antigen presenting cells (APC) enhances the potency of recombinant protein CD8(+) T cell vaccines. Recent comparisons of recombinant protein-based dendritic cell (DC) targeting vaccines revealed differences in cross-presentation and identified CD40 as a potent human DC receptor target for antigen cross-presentation. Contrary to in vitro-derived monocyte (mo)DC, we found that interferon-alpha (IFNα) stimulation of human blood-derived DC was necessary for an antigen-specific IFNγ CD8(+) T cell response to a CD40 targeted cancer vaccine. Importantly, targeting an adjuvant in the form of IFNα to DC increased their potency to elicit antigen-specific production of IFNγ by CD8(+) T cells. Thus, we introduce the concept of DC adjuvant targeting to enhance the potency of vaccination.

PMID: 28743486 [PubMed - as supplied by publisher]

http://ift.tt/2v1SxYj